Quarterly Result18 Jun 2025, 02:22 pm
Ajanta Pharma's Revenue Surges by 10% in FY 2025, Reports Pristine Balance Sheet
AI Summary
Ajanta Pharma Ltd, a leading pharmaceutical company, reported a 10% growth in revenue from operations, reaching INR 4,648 crore in FY 2025. The company's EBITDA grew by 7% to INR 1,260 crore, with a margin of 27%. The Profit After Tax (PAT) grew by 13% to INR 920 crore, with a PAT margin of 20%. The balance sheet position remains strong with INR 615 crore as cash and liquid investments. The company generated free cash flow of INR 694 crore in FY 2025, which is 75% of PAT. Ajanta Pharma distributed a total of INR 700 crore to shareholders in the form of dividend and buyback.
Key Highlights
- Revenue from operations grew by 10% to INR 4,648 crore
- EBITDA grew by 7% to INR 1,260 crore with 27% margin
- Profit After Tax (PAT) grew by 13% to INR 920 crore with 20% margin
- Generated free cash flow of INR 694 crore in FY 2025, which is 75% of PAT
- Distributed a total of INR 700 crore to shareholders in the form of dividend and buyback